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Background: Nonalcoholic fatty liver disease (NAFLD) is a common liver disorder that currently lacks effective
treatment. Berberine (BBR), a botanic compound isolated from traditional Chinese medicine, exhibits a potent
therapeutic potential for the metabolic disease. The current study aimed to understand the mechanisms underlying
the therapeutic effect of BBR in NAFLD.
Methods: We performed systematical analyses on hepatic expression profiles of mRNAs and long noncoding RNAs
(lncRNAs) in a high-fat diet (HFD)-induced steatotic animal model with or without BBR treatment. The study was
conducted by using the methods of bioinformatics, including hierarchical clustering, gene enrichment and gene
co-expression networks analysis. The effect of BBR on the expression profile of some interesting genes was
confirmed by quantitative RT-PCR and further studied in a human hepatic cell line, Huh7.
Results: We found that a large group of genes including 881 mRNAs and 538 lncRNAs whose expression in the
steatotic liver was reversed by BBR treatment, suggesting a global effect of BBR in modulating hepatic gene
expression profiles. Among the BBR-regulated genes, we identified several modules and numerous significant genes
that were associated with liver metabolism and NAFLD-related functions. Specifically, a conserved lncRNA,
MRAK052686, was found strongly correlated with the antioxidant factor Nrf2, and both genes were down-regulated
by the steatotic liver. Moreover, the reduced expression of MRAK052686 and Nrf2 was completely reversed by BBR
treatment, suggesting a new mechanism accounting for the therapeutic effect of BBR.
Conclusions: The findings for the first time provide a new genetic insight into the pharmaceutical mechanism of
BBR in protecting against NAFLD.
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Nonalcoholic fatty liver disease (NAFLD) has become a
worldwide health problem that influences approximately
20–30% of the general population and its prevalence
is continuously increasing [1,2]. NAFLD is closely
associated with obesity, hyperlipemia and type 2 diabetes,
and thus often regarded as atypical hepatic manifestation
of the metabolic syndrome [3]. Under certain circum-
stances, NAFLD can progress from hepatic steatosis to
steatohepatitis, leading to an increased susceptibility of* Correspondence: xiapu_fudan@163.com; happy20061208@126.com
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unless otherwise stated.cirrhosis and hepatocellular carcinoma [2]. However, there
is still a limitation in both mechanistic understanding and
clinical management of the disease. Besides life style
intervention, several medications, e.g., Metformin, vitamin E
and Pioglitazone, are currently applied in the clinic for
treatment of NAFLD [4,5]. However, these medications
often exhibited a limited efficacy and considerable side
effects. Therefore, much effort has been focused on the
development of new therapeutics for NAFLD.
Berberine (BBR), isolated from the herb Rhizoma
Coptidis, has been widely used in traditional Chinese
medicine to treat diarrhea and many other inflammatory
diseases [6]. Recent studies have revealed a novel
therapeutic role of BBR in metabolic disorders, includinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cholesterol-lowering drug via a unique mechanism
distinct from statins [9]. These findings suggest a potential
therapeutic activity of BBR for NAFLD. Indeed, both
in vitro and in vivo studies from our previous work and
many others have shown that BBR profoundly inhibited
lipid synthesis and accumulation in hepatocytes, attenuated
hepatic steatosis and hyperlipidemia, and prevented the
progression of NAFLD [10-14]. Mechanistically, the
therapeutic activity of BBR has been suggested to
attribute to its effects of overcoming insulin resistance,
reducing endoplasmic reticulum (ER) stress and regulating
the signaling pathways, such as the AMPK and JNK
pathways [15-18]. More recently, BBR has been shown to
modulate gut microbiota, which also account for the
therapeutic effect of BBR on the metabolic diseases [19]. It
thus appears that multiple mechanisms are involved in the
therapeutic effect of BBR, leading us to hypothesize
that BBR may have a global effect in modulating gene
expression profile in the liver and thereby protecting
against hepatic steastosis.
Long noncoding RNAs (lncRNAs) are a novel class of
RNA transcripts that are more than 200 bp in length
and have little or no protein-coding capacity [20].
According to chromosomal position relative to coding
RNAs, lncRNAs are mainly grouped into intergenic,
intronic, sense and antisense non-coding RNAs [21].
Most lncRNAs show moderately evolutional conservation
and specific transcription [22]. Recently, lncRNAs have
been shown widely involved in epigenetic regulation via
their direct or indirect interactions with chromatins [23].
Acting as important regulatory molecules, miscellaneous
lncRNAs are critically complicated diverse biological
processes from normal development and human diseases
[24,25]. However, there are little studies on lncRNA
in NAFLD. In an attempt to further understand the
mechanisms underlying the therapeutic effect of BBR,
we performed systematical analyses on hepatic expression
profiles of mRNAs and lncRNAs in a high-fat diet
(HFD)-induced steatotic animal model with or without
BBR treatment as reported in the present study.
Materials and methods
Animals
Animal studies were approved by the Animal Use and
Care Committee of Fudan University and were in
conformity with the US Public Health Service Policy
on Humane Care and Use of Laboratory Animals.
Total 24 healthy male Sprague-Dawley rats weighing
around 200 g were obtained from the Animal Development
Center, Chinese Academy of Sciences, Shanghai. All rats
were acclimated for 1 week before initiation of the
experiment and maintained on a 12/12 h light/dark
cycle with free access to food and water. The animalswere divided to the following three groups (8 rats per
group): (i) Control group (ND group), received a
regular rodent chow diet (62.3% carbohydrate, 12.5%
fat and 24.3% protein in total calories); (ii)HFD group,
fed a HFD (32.6% carbohydrate, 51.0% fat and 16.4%
protein) for 24 weeks; and (iii) HFD + BBR group,
after 8 weeks of HFD feeding, rats were orally treated
with BBR (Sigma, St. Louis, USA) at a dose of
200 mg/kg/day via a lavage needle and fed on HFD
feeding for 16 weeks. Animals received intraperitoneal
glucose tolerance tests (IPGTT), weekly measurements of
body weight and food intake, and monthly tests of fasting
serum insulin and glucose as described previously [12].
Hepatic lipids were extracted according to the
method of Folch et al. [26] and triglyceride content
was tested as described previously [27]. Fasting serum
levels of total cholesterol and low-density lipoprotein
cholesterol (LDL-c) were measured using an Amplex Red
Cholesterol Assay Kit (A12216, Molecular Probes
Invitrogen Detection Technologies) according to the
manufacturer’s protocol.Histological examination
All liver samples were collected after animals were
sacrificed in 24th week of the treatment and subsequently
fixed in phosphate-buffered 10% formalin. The right
lateral lobule of each liver was embedded in paraffin
blocks and stained with hematoxylin and eosin (H&E)
examining the pathologic features of the liver.Microarrays of mRNAs and lncRNAs
Arraystar Rat LncRNA microarrays (accession in NCBI
Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/
geo: GPL15690) were used for measuring the expression
profiles of lncRNAs and mRNAs in total 15 rats (i.e.,
3 groups at 5 replicates). The sample preparations
and microarray hybridization were performed based
on the manufacturer’s protocols. Briefly, 1 μg of total
RNA from each sample was amplified and transcribed
into fluorescent cRNA using Agilent’s Quick Amp
Labeling kits according to the manufacturer’s proto-
col (version 5.7, Agilent Technologies). The labeled
cRNAs were hybridized onto the Rat LncRNA Arrays
(4×44K, Arraystar, Rockville, USA). After washing,
the arrays were scanned by the Agilent Scanner G2505B.
Raw signal intensities were normalized in quantile method
by GeneSpring GX v11.5.1. After filtration of low intensity
RNAs, those RNAs with flags in Present or Marginal at
least 1 out of 15 samples were chosen for further analysis.
Differentially expressed genes were identified by using the
Limma package [28]. The threshold set for significantly
differential genes was an absolute log value of fold
change ≥ 0.6 and a p value < 0.05.
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We took Euclidean distance with a complete linkage to
hierarchically cluster the genes across the samples.
Unsupervised hierarchical clustering and the visualization
of heatmap were performed using the R platform
(http://www.r-project.org/). Gene function enrichment
analysis was performed by using DAVID [29]. The
significance of enrichment was calculated by hyper-
geometric test and adjusted by Benjamini method.
GO (gene ontology) and KEGG (kyoto encyclopedia




We analyzed associations between gene modules and the
traits by using WGCNA (weighted correlation network
analysis) package [32]. The package assessed module-trait
relationships by correlating of each module eigengene (the
first principal component of gene expression in the
module) with the traits.
Construction of gene co-expression networks
We constructed and analyzed the co-expression network
of lncRNAs and mRNAs using WGCNA package. The
weight of edges was scaled by a soft power of correlation
coefficient of parewise genes, and the soft power was set
to 16 after stimulation. The visualization and layout of
network were achieved by cytoscape software [33].
Prediction for protein-coding potential and interaction
propensity of lncRNAs
The protein-coding potential of lncRNAs was predicted by
PhyloCSF which calculates codon substitution frequencies
(CSF) determining whether a multispecies nucleotide
sequence is conserved protein-coding region [34]. The
more positive value of CSF indicates a higher potential to
code protein, vice versa. Multiple alignments of 8 vertebrate
genomes are downloaded from UCSC (http://genome.ucsc.
edu/). We used catRAPID to predict the interaction
propensity of lncRNAs with proteins [35]. The software
catRAPID computes interaction propensity (IP, a measure
based on physico-chemical profiles of ribonucleoprotein
complexes) and discriminative power (DP) for assessing the
potential of interaction. DP above 75% represents highly
confident IP.
Identification of human homologous of the lncRNA
MRAK052686
According to genome-wide alignment from UCSC (http://
genome.ucsc.edu) and chromosomal position, we found
that human MRAK052686 is located around ZBTB20. A
direct searching of MRAK052686 in human genome
indicated the same chromosomal location as mentionedabove. By searching this human locus in ENSMBL database
(http://www.ensembl.org) and then aligning sequences, we
found 6 of 11 non-coding transcripts with a high similarity
to rat MRAK052686 (Additional file 1: Table S1 and
Additional file 2: Figure S1). These six lncRNAs were thus
regarded as human homologues ofMRAK052686.
Cell culture, treatment and intracellular lipid staining
Huh7, a human hepatoma cell line, was obtained from
American Type Culture Collection (Manassas, VA) and
routinely cultured in DMEM supplemented with 10%
fetal bovine serum. For treatment, a stock solution of
100 mM oleic acid with 11% (w/v) fatty acid-free BSA
was prepared. When reaching a 70% confluence, cells
were washed with PBS and exposed to 100 μM OA for
24 h in the presence or absence of 10 μM BBR. For
intracellular lipid staining, cells were washed with PBS
three times and fixed with 4% paraformaldehide for
30 min. Intracellular lipids were stained with Nile
Red (Sigma, St. Louis, USA) for 15 min and nuclei
stained with DAPI for an additional 5 min. Images were
photographed with an inverted fluorescence microscope
(Leica DM2000, Wetzlar, Germany).
Real-time quantitative PCR
All rats were euthanized and their livers were collected after
24 weeks treatment. Total RNA was isolated from liver
tissues using Trizol reagent (Invitrogen, Carlsbad, CA).
cDNA was synthesized by reverse transcription in a 20 μL
reaction system using PrimeScript kit (Takara, Tokyo,
Japan). The reverse transcription reactions were conducted
at 37°C for 15 min and inactivated at 85°C for 30s using an
automatic thermocycler according to manufacturer’s
instruction. Real-time quantitative PCR (RT-qPCR) was
performed with an Applied Biosystems 7500 using SYBR
Premix EX Taq (Takara, Tokyo, Japan). A total 10 μL
reaction mixture contained of 5 ng sample cDNA, 5 μM
specific forward and reverse primers, and 5 μL SYBR
Premix EX Taq. The sequences of primers used for
RT-qPCR are shown in Additional file 1: Table S2.
The PCR reaction was consisted of an initial denaturation
cycle at 95°C for 10 min and 40 amplification cycles of 95°C
for 15 s and 60°C for 1 min. The relative gene expression
was calculated using the 2-ΔΔCt method [27]. The
same reaction was carried out in triplicate with β-actin as
an internal control. Experiments of each condition were
conducted in 3 replicates.
Statistical analysis
All data were presented as mean ± SEM. Significance
was assessed by one-way ANOVA followed by Tukey’s
test and LSD for multiple comparisons. Chi-square test
was used to assess the significance of variables in the
contingency table. All statistics were performed in R
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significant.
Results
BBR ameliorates hepatic steatosis in HFD-fed rats
BBR has been reported to prevent the development of
NAFLD in animal models [12,36,37]. To confirm the
therapeutic effect of BBR, we examined the effect of
BBR on the liver in HFD-induced obese rats. As shown
in Figure 1, HFD-fed animals exhibited moderate to
severe hepatic steatosis with typical histological features
of cell swelling and large amount of fat accumulations
within hepatocytes. Remarkably, HFD-induced steatosis
was evidently ameliorated by BBR treatment, as reflected
in a significant reduction of ballooning cells and Mallory
bodies (Figure 1A). Moreover, BBR treatment significantly
lowered hepatic TG contents and serum levels of TC
and LDL-c by 13.7%, 28.1% and 41.9%, respectively,
in comparison with the HFD-fed animals (all p < 0.05,
Figures 1B and 1C).
BBR systematically modulates hepatic gene expression
In an attempt to understand the molecular basis of
the efficacy of BBR, we performed a microarray-based
analysis of hepatic gene expression profiles in ND,
HFD and HFD + BBR treated animals. After normalization
and filtration of microarray data, total 14, 319 mRNAs
and 9, 531 lncRNAs were identified for further analysis.Figure 1 BBR ameliorates hepatic steatosis in HFD-fed rats. (A)The live
HFD plus Berberine (HFD + BBR)were stained with hematoxylin and eosin. P
in the white box. Ballooning cells and Mallory bodiesare shown in black an
and LDL-c levels were measured in the experimental animals as described
p < 0.05 versus HFD (assessed by one-way ANOVA followed by Tukey’s mu
diet; TG, triglyceride; TC, cholesterol.By comparison of HFD + BBR with HFD group, we identi-
fied 531 and 407 differentially expressed mRNAs and
lncRNAs, respectively (Figure 2A). In addition, the second
comparison of HFD with ND group revealed that 4,
612 mRNAs (including 2, 719 up-regulated and 1,
893 down-regulated mRNAs) and 2, 813 lncRNAs
(consisting of 818 up-regulated and 1, 995 down-
regulated lncRNAs) were differentially expressed, of
which 362 mRNAs and 284 lncRNAs were overlapped with
the first comparison (Figure 2A). Among the overlapped
and reversely expressed genes in two comparisons, BBR
significantly up-regulated more lncRNAs (241 lncRNAs
vs. 121 mRNAs) and down-regulated more mRNAs
(233 mRNAs vs. 37 lncRNAs) (Figure 2A, p < 1.0E-10,
chi-squared test). Moreover, among the 7,425 genes
whose expression was altered in HFD group, 6,344
(85.4%) genes including 2,399 lncRNAs were reversed
towards a normal expression profile after BBR treatment
(Figure 2B, p < 1.0E-10). In addition, by comparing HFD
and HFD+ BBR with ND group, respectively, we found
much fewer differences in mRNA and lncRNA expression
between HFD + BBR and ND than that between HFD and
ND groups (476 mRNAs and 374 lncRNAs versus 2131
mRNAs and 1402 lncRNAs, Additional file 3: Figure S2).
Taken together, the data suggest a potent effect of
BBR on a global regulation of hepatic gene expression in
the steatotic liver trending towards a normal profile,
including abundant lncRNAs.rs isolated from rats fed with a normal diet (ND), high-fat diet (HFD) or
hotographs are at 200 ×magnification. A large magnification is shown
d red arrows, respectively. (B) Hepatic TG contents, and (C) serum TC
in “Methods”. Data are mean ± SEM. * p < 0.05, ** p < 0.01 versus ND; #
ltiple comparison tests). BBR, berberine; HFD, high-fat diet; ND, normal
Figure 2 BBR systematically regulates hepatic gene expression. (A) A Venn diagram of differentially expressed genes in the experimental
rats. The cyan and grey arrows represent the comparisons of HFD + BBR with HFD group (HFD + BBR:HFD) and HFD with ND group (HFD:ND),
respectively. The upward arrows indicate up-regulation and downward, down-regulation. Sloped arrows in brackets indicate genes whose expression
is not significantly altered but meets our criteria of BBR-regulated genes. Numbers in brackets indicate a subset of the number immediately above. The
red number is the count of BBR-regulated genes. (B) BBR reversed most differentially expressed genes in HFD relative to ND group. The numbers in
the center indicate the count of genes in corresponding quadrant. The p value was calculated with the Chi-squared test.
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In order to further characterize the effect of BBR on
hepatic gene regulation, we specifically grouped the genes
whose expression was potentially regulated by BBR. To
this end, we used the following criteria to determine the
genes as BBR-regulated genes: (i) the gene expression was
inversely changed in two comparisons, and (ii) absolute
log value of fold change ≥ 0.6 in the first comparison
between HFD + BBR and HFD groups. Accordingly,Figure 3 Hierarchical clustering and functions enrichment analyses of
(grey), HFD (purple) or HFD + BBR (cyan) group. Each row indicates genes,
column. Each cell of the heat-map reflects expression value above or below t
on the upper left. Based on gene clustering tree (Additional file 5: Figure S3),
most left color column: brown, blue, red, green, dark golden, light blue and s
modules. The number on the right of vertical axis indicates the count of enric
highlight in bold. The color bars on the left of vertical axis represent the mod
in Additional file 5: Table S3.total 881 mRNAs and 538 lncRNAs were identified as
BBR-regulated genes whose expression patterns were
reversed after BBR treatment in comparison to HFD
group (Figure 2A, Additional file 4: Table S3).
For assessing the association of lncRNAs with mRNAs,
we performed hierarchical clustering of BBR-regulated genes
across the three experimental groups. HFD+BBR group ex-
hibited a similar expression profile of BBR-regulated genes
to the ND group (Figure 3A). Furthermore, we dividedBBR-regulated genes. (A) Each column represents samples from ND
in which lncRNAs are labeled with black bars on the most right
he pool of control rats fed ND. The legend of expression value is shown
BBR-regulated genes are divided into seven modules, indicating with the
almon. (B) Representative enriched functions for seven BBR-regulated
hed genes in corresponding function. The NAFLD-related functions
ules. More details of the enriched functions for each module are shown
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BBR-regulated modules) based on gene clustering trees
(Additional file 5: Figure S3). These modules represent dis-
tinct expression patterns. In these modules, lncRNAs were
not uniformly distributed, whereas lncRNAs were evidently
enriched in the dark golden and light blue modules
(Figure 3A).
Based on the above seven BBR-regulated modules, we
assessed the correlation of NAFLD-related traits with
the module eigengenes using WGCNA package [32]. We
found that salmon module was mostly correlated with
triglyceride metabolism and red module associated with
lipoproteins (Additional file 6: Figure S4). Of note, function
enrichment analysis by using DAVID [29] indicated that
the salmon and red modules are likely associated with
NAFLD, including the genes involved in endoplasmic
reticulum (ER) function and fatty acid metabolism
(Figure 3B, and Additional file 1: Table S4). In addition,
mRNAs in dark golden module is also related to NAFLD,
including the genes involved in fat-soluble vitamin
metabolic process. Collectively, these data indicate that a
large number of BBR-regulated genes including lncRNAs
are indeed functionally associated with NAFLD (especially
those from salmon, red and dark golden modules).
The lncRNA MRAK052686 is a significant BBR-regulated gene
Given the numerous BBR-regulated genes as identified
above, we assessed gene significance by analyzing association
of gene expression with traits. The genes with a high signifi-
cance for trait and strong correlation in module were char-
acterized as potentially important genes. Accordingly, we
identified two significant lncRNAs, MRAK052212 and
MRAK080926, from the salmon module that was highlyFigure 4 Co-expression sub-networks derived from enriched genes in
genes and their first neighboring genes. The threshold for edges of co-exp
and Adh1, were identified by enrichment analysis showing in Figure 3B. Th
are highlighted in cyan color. Rectangles and circles represent lncRNAs andcorrelated with triglyceride metabolism (Additional file 7:
Figure S5A). The function annotation of associated mRNAs
indicated thatMRAK052212 andMRAK080926may partici-
pate in lipid metabolism and ER to Golgi vesicle-mediated
transport process (Additional file 1: Table S5). Further-
more, we identified another two most significant protein-
coding genes from the red module, including Lyz2 and
Tnfrsf18, which were highly correlated with LDL trait
(Additional file 7: Figure S5B). Lyz2 is suggested to be as-
sociated with catabolic process in ER according to gene
ontology (GO). Then, we analyzed co-expression sub-
networks from the significant genes and their first
neighbor genes in each NAFLD-related module. In the
sub-networks derived from salmon and red modules, we
identified three potentially important lncRNAs, including
AF034247, MRuc007jok and BC166462, which were all con-
nected with enriched protein-coding genes (Additional file
8: Figure S6). In the dark golden module, a sub-network
was delineated based on two enriched and strong co-
expressed genes, Eif2ak2 (also known as Prkr) and Adh1
(Pearson’s correlation coefficient, R = 0.59, p = 0.02).
Interestingly, in this sub-network we found an
lncRNA, MRAK052686 that was strongly associated with
Eif2ak2 (R = 0.59, p = 0.022) and Nrf2 (also known as
Nfe2l2, R = 0. 91, p = 2.7e-06) (Figure 4). Both Eif2ak2 and
Nrf2 have been previously documented being associated
with the pathogenesis and progression of NAFLD [38]. In
addition, according to the KEGG Pathway Database, Nrf2
was a direct downstream target of Eif2ak2 in ER stress
response pathways. Furthermore, the lncRNA MRAK052686
was co-expressed with several other NAFLD-related
genes, including the fatty acid binding protein Fabp7
and Gcs1, which are involved in ER protein processingdark golden module. Nodes of sub-networks consist of enriched
ression network is 0.25 for weighted correlation. The red genes, Eif2ak2
e potentially important lncRNA MRAK052686 and its associated mRNAs
mRNAs, respectively.
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that the lncRNA MRAK052686 may play important roles
in NAFLD by affecting the genes that regulate cellular
stress response and protein processing in ER. Besides
MRAK052686, we found more lncRNAs (accounting
for 65%) connected to the NAFLD-related genes in
sub-networks of dark golden and salmon modules
(Figure 4 and Additional file 8: Figure S6), further indicating
an important role of lncRNAs in NAFLD.
MRAK052686 is located in 3’UTR of protein-coding gene
Zbtb20, which is an important regulator of glucose homeosta-
sis and has been reported to associate with liver dysfunction
[39]. However, we found no difference in Zbtb20 expression
between HFD+BBR and HFD groups (data not shown) and
no correlation of Zbtb20 to MRAK052686. This suggests that
MRAK052686 is a transcript independent of Zbtb20. Further
analysis indicated that codon substitution frequency of
MRAK052686 is strongly negative (Additional file 9: Figure
S7). Moreover, we found no protein sequence significantly
matched with MRAK052686 from NCBI reference protein
database (data not shown), further suggesting that
MRAK052686 has no or little potential to code protein.
BBR restores the decreased expression of MRAK052686
and Nrf2 in steatotic liver
Having identified the lncRNA MRAK052686 and the
related gene Nrf2 from the NAFLD-related modules,
we wanted to clarify whether their expression wasFigure 5 Co-expression of MRAK052686 and Nrf2 across three groups o
measured by RT-qPCR and normalized by β-actin expression. Significance was
tests. Data are shown as mean ± SEM (n≥ 4). Pearson’s correlation coefficientcorrelated in NAFLD and whether regulated by BBR
treatment. By conducting RT-qPCR assays, we confirmed
that both MRAK052686 and Nrf2 expression was signifi-
cantly down-regulated in the livers of HFD group com-
pared with the controls (p < 0.01, Figure 5A). Moreover,
the reduced expression of MRAK052686 and Nrf2 was
markedly reversed by BBR treatment (p < 0.05, Figure 5A).
In addition, a significant positive correlation between
hepatic expression levels of MRAK052686 and Nrf2 existed
across ND, HFD and HFD + BBR groups (R = 0.76,
p = 0.00015, Figure 5B), further supporting a strong
co-expression profile of these two genes in the liver.
By searching MRAK052686 homolog in human genes,
we found 6 homologous variants from ENSMBL database
(Additional file 1: Table S1 and Additional file 2: Figure S1).
Among 6 variants, four of them (i.e., ZBTB20-008, -013, -016
and -017) were detected in human Huh7 hepatocytes
(Figure 6). To further clarify whether the expression of these
noncoding transcripts is also associated with hepatic steatosis
in human, we treated Huh7 cells with oleic acid (OA) [26],
which is regarded as an established steatotic cell model. As
shown in Figure 6, cells exposed to 100 μM OA for 24 h
resulted in an evident lipid accumulation, whereas BBR treat-
ment significantly prevented the OA-induced steatosis
(Figure 6A). In keeping with the findings from the HFD-fed
animals, all the detectable variants of noncoding ZBTB20
transcripts were significantly down-regulated in OA-treated
hepatocytes, which were.completely reversed by BBRf the rats. (A) Levels of MRAK052686 and Nrf2 expression in livers were
assessed by one-way ANOVA followed by Tukey’s multiple comparison
(R) and corresponding p value of the fitted line are shown in (B).
Figure 6 The expression pattern of noncoding ZBTB20 transcripts in human Huh7 cells. (A) Huh7 cells were treated for 24 h with OA in
the presence or absence of BBR (10 μM), and then stained with Nile Red. Photographs were taken by a fluorescence microscopy and shown at
400 ×magnification. (B) Four human homologues of MRAK052686 were measured by RT-qPCR in Huh7 cells treated with BBR, OA or BBR + OA as
indicated (n = 3). Data are shown as mean ± SEM. *p < 0.05, vs control and #p < 0.05, vs OA alone. Significance was assessed by one-way ANOVA
followed by Tukey’s multiple comparison tests. OA, oleic acid; BBR, berberine.
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only indicate the connection of noncoding ZBTB20
transcripts with hepatic steatosis, but also suggest that
the protective effect of BBR against NAFLD is associated
with the expression of these lncRNAs.Discussion
Multiple lines of evidences from both in vivo and in vitro
studies have demonstrated a therapeutic potential of the
botanic compound BBR in metabolic diseases, including
obesity and diabetes [7,8,10-14]. In the present, we were
Yuan et al. Journal of Translational Medicine  (2015) 13:24 Page 9 of 11able to confirm the effect of BBR in amelioration of
NAFLD in HFD-induced obese rats as reported previously
[12,14]. By analyzing gene expression profiles, we identified
5, 271 mRNAs and 3, 265 lncRNAs, which displayed differ-
ential expression patterns among the control, HFD and
HFD+BBR treated animals. We further refined a large
group of BBR-regulated genes, including 881 mRNAs and
538 lncRNAs whose expression was reversed between HFD
and HFD + BBR groups, demonstrating a potent effect
of BBR in globally altering hepatic gene expression.
Moreover, by modularization of the BBR-regulated
genes, we delineated several modules and identified
numerous significant genes exhibiting a wide association
with liver metabolism and NAFLD-related functions.
The findings thus, for the first time, provide a genetic
basis for understanding the pharmaceutical mechanism of
BBR in protection against multiple metabolic diseases,
including NAFLD.
Of interesting, not only were over 800 of BBR-regulated
mRNAs identified in the current study, but also more than
500 aberrant lncRNAs in NAFLD were reversed by BBR
treatment (Figure 2A). The number of altered lncRNAs
was comparable with that of mRNAs. Although the
precise roles of these lncRNAs in NAFLD are currently
unknown, lncRNAs have emerged as important regulators
of gene expression related to metabolic homeostasis or
dysfunction. For instance, it was reported that near two
hundreds of lncRNAs were regulated during the process
of adipogenesis and many of them were bound at their
promoters by key transcription factors such as PPARγ and
CEBPα [40]. Furthermore, RNAi-mediated loss of func-
tion screens identified numerous lncRNAs that were
required for proper adipogenesis [41]. There is a large
body of evidences that lncRNAs can regulate gene expres-
sion both in cis and in trans by forming RNA-protein,
DNA-RNA, protein-DNA and RNA-RNA interactions [41].
In the current study, we found that a total of 538 lncRNAs
were regulated in the liver by BBR treatment in
HFD-induced obese rats. Among these BBR-regulated
lncRNAs, a set of lncRNAs was significantly associated
with triglyceride trait (Additional file 8: Figure S6). In the
analysis of co-expression sub-networks, we identified
numerous lncRNAs were located in the salmon and dark
golden modules, which are functionally linked with
NAFLD-related genes (Figure 4 and Additional file 8:
Figure S6). A significant example of these lncRNAs is
MRAK052686. We found that MRAK052686 expression
associated with Eif2ak2 and Nrf2 (Figure 4), the two genes
that are critically involved in NAFLD. By bioinformatics
prediction, we found the interaction propensity and
discriminative power of Nrf2 and Eif2ak2 interacting with
MRAK052686 are far stronger than that of the control
genes Actb and Gapdh (Additional file 10: Figure S8).
Indeed, a strong co-expression of MRAK052686 and Nrf2was demonstrated by either microarray analysis or the
experimental data from HFD-fed animals (Figure 5).
This implies a potential role of MRAK052686 in regulation
of Nrf2 expression.
Nrf2 is a master transcription factor that regulates
expression of many genes that are involved in antioxi-
dant, metabolism and ER stress response [38,42]. In
mammalian, Nrf2 is regarded as a major cellular sensor
of oxidative stress, which constitutes downstream the
PERK (PKR-like ER-kinase) pathway during ER stress
response [41]. Upon PERK activation, Nrf2 is activated
and binds to the antioxidant response elements in the
regulatory regions of target genes, thereby regulating
ER stress response [43,44]. Besides, Eif2ak2, another
associated gene with MRAK052686, is actually a
homologue of PERK. Moreover, Gcs1 that was also
co-expressed with MRAK052686 functions in ER protein
processing and regulates ER stress response. Indeed, ER
stress has been well documented as a pivotal pathogenic
event contributing to the process of hepatic steatosis
[45,46]. The findings that MRAK052686 associates with
several key molecules of the ER stress response pathways
suggest that MRAK052686 may play important roles in
NAFLD by affecting ER stress response, which warrants
further investigations.
In the present study, another key finding is that
most of the aberrantly expressed genes, including
numerous lncRNAs, in HFD-induced hepatic steatosis
were reversed by BBR treatment. In modularization
of the sub-networks from salmon and dark golden
modules, much more lncRNAs were co-expressed
with enriched NAFLD-related mRNAs. This not only
demonstrates a global effect of BBR on the alteration
of gene profiles, but also suggests a population of
lncRNAs as a whole target of the therapeutic action
of BBR. Correspondingly, BBR exerts its effect to
alleviate NAFLD through a systematic modulation of
gene expression including lncRNAs in the liver, pro-
viding a potential novel therapeutic agent for the
treatment of NAFLD.
Conclusions
By analyzing hepatic gene expression profiles, we
found that HFD-induced steatosis in rats resulted in
a globe alteration in hepatic gene expression, which
was significantly reversed by BBR treatment. Several
modules of BBR-regulated genes, including abundant
lncRNAs, were identified by bioinformatics analysis.
Among these BBR-regulated genes, we found that the
lncRNA MRAK052686 and its associated gene Nrf2
appear implicating in the pathogenesis of NAFLD.
Thus, the study provides a new genetic insight into
the pharmaceutical mechanism of BBR in protecting
against NAFLD.
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Additional file 1: Table S1. Sequence similarity of transcript variants of
human homologous with rat MRAK052686. Table S2. The primers of
genes for RT-qPCR. Table S4. Detailed function annotation of genes in
seven modules. Table S5. Function annotation of mRNAs associated with
MRAK052686.
Additional file 2: Figure S1. Human chromosomal locations of
MRAK052686 and its homologs. The conserved regions between MRAK052686
and its homologs were connected with dash lines. The thick and thin bars in
gene models indicate protein-coding and non-protein coding regions,
respectively.
Additional file 3: Figure S2. A Venn diagram illustrates the number
of genes that were differentially expressed in comparisons of HFD-
or BBR-treated with ND group. The cyan arrows represent the
comparison of HFD+BBR with ND group (HFD+BBR:ND) and grey
arrows for the HFD:ND comparison. The upward and downward
arrows indicate up-regulated and down-regulated expression,
respectively.
Additional file 4: Table S3. The list of BBR-regulated genes.
Additional file 5: Figure S3. Hierarchical clustering tree of BBR-
regulated genes. Each row represents the rat sample from ND (grey),
HFD (purple) or HFD+BBR (cyan) group. The columns indicate BBR-
regulated genes, which are divided into seven modules (the top color
column from right to left: brown, blue, red, green, dark golden, light blue
and salmon). Each cell of the heat-map reflects expression value above or
below pool control level. The legend of expression value is shown on the
upper left.
Additional file 6: Figure S4. Relationship of gene modules with rat
traits. Each row corresponds to a module eigengene, column to a trait.
Each cell contains the corresponding correlation (p value, calculated by
WGCNA package) and is colored by correlation according to the color
legend on the right. CHOL, cholesterol; TG, triglyceride; HDL, high density
lipoprotein; LDL, low density lipoprotein. The left color bars represent the
modules consistent with Figure 3.
Additional file 7: Figure S5. Gene significance of traits in salmon
and red modules. (A) Gene significance of triglyceride in salmon
modules. (B) Gene significance of LDL (low density lipoprotein) in
red modules. The definition and calculation of gene significance
and module correlation see Methods part. Circle and star points
represent mRNAs and lncRNAs, respectively. The dash lines on the
upper right are threshold sets for most significant genes labeled by
larger markers and gene names. The linear fit curve with Pearson
correlation (R) and significance (p value) of scatter points are
shown.
Additional file 8: Figure S6. Co-expression sub-network derived from
enriched genes in salmon and red modules. Nodes of sub-network
consist of enriched genes and their first neighboring genes. The threshold
of co-expression network is 0.25 for weighted correlation. The red genes
were identified by enrichment analysis showing in Figure 4. The potentially
important lncRNAs are labeled in cyan color. Rectangles and circles represent
lncRNAs and mRNAs, respectively.
Additional file 9: Figure S7. Location and coding potential of
MRAK052686. MRAK052686 (blue) are transcribed from sense strand of
protein-coding gene Zbtb20 (green). The thick and thin bars of Zbtb20
represent protein-coding and untranslated regions, respectively. The higher
codon substitution frequency corresponds to stronger protein-coding
potential.
Additional file 10: Figure S8. The heat-map indicating an interaction of
MRAK052686 with Nrf2 and Eif2ak2. The vertical index on the left of each
heat-map is position of corresponding protein. IP and DP are abbreviations
of interaction propensity and discriminative power, respectively. Higher IP
and DP indicate more potential interaction.Competing interests
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